# DESCRIPTION

## FIELD

- introduce peptidomimetic foldamers

## BACKGROUND

- motivate protein-protein interactions
- describe limitations of peptides
- introduce foldamers
- discuss oligourea foldamers
- highlight importance of foldamer research
- motivate design of new foldamer architectures

## SUMMARY

- introduce peptide-oligourea hybrids
- describe structure of hybrids
- highlight advantages of hybrids
- describe Xu residue
- provide examples of Xu residue
- describe amino urea residues
- provide examples of amino urea residues
- describe peptide-amino urea hybrid compounds
- provide examples of hybrid compounds
- describe glucagon-like peptide-1 (GLP-1) hybrids
- describe pharmaceutical composition
- describe method of treating disease

## DETAILED DESCRIPTION

- provide context for invention
- incorporate prior art by reference
- describe oligourea foldamers
- introduce peptide-amino urea hybrid foldamer compounds
- describe advantages of peptide-oligourea hybrid compounds
- define terms used in disclosure
- explain use of transitional phrases
- define "at least one" phrase
- describe method steps
- define "peptides" and "polypeptides"
- define "amino" and "amine"
- define "amino acid" and "amino acid sidechain"
- describe urea group
- define "peptide precursor" and "oligourea"
- define "compound"
- define "amido"
- define "cyano"
- define "nitro"
- define "azido"
- explain abbreviations
- define "alkyl"
- define "alkenyl"
- define "alkynyl"
- define "alkylene"
- explain "unsubstituted" and "substituted"
- provide examples of substituents
- define "hydroxyl"
- define "heterocycle"
- define "heteroaryl"
- define chemical groups
- define aryl group
- define substituted aryl group
- define carboxyl group
- define cycloalkyl group
- define substituted cycloalkyl group
- define heterocycloalkyl group
- define substituted heterocycloalkyl group
- define alkenyl group
- introduce imidazole group
- introduce aralkyl group
- introduce guanidine group
- describe oligourea compounds
- describe peptide-oligourea hybrid compounds
- describe structure of peptide-oligourea hybrid compounds
- describe properties of peptide-oligourea hybrid compounds
- describe GLP-1 oligourea hybrid compounds
- describe bioactivity of GLP-1 peptide-oligourea hybrid compounds
- describe secondary structure of peptide-oligourea hybrid compounds
- define peptide-oligourea hybrid compounds
- describe structural variations
- specify oligourea portion linkage
- detail amino urea residue count
- introduce chemical modifications
- describe pharmaceutical forms
- outline pharmaceutical composition
- specify effective amount
- describe medicinal uses
- discuss salt forms
- detail crystal forms and solvates
- describe chiral centers and isomers
- define pharmaceutically acceptable salts
- define prodrugs
- motivate prodrugs
- describe prodrug forms
- exemplify prodrugs
- define protecting groups
- describe protected forms
- exemplify protecting groups
- introduce formulations
- describe routes of administration
- describe pharmaceutical compositions
- exemplify pharmaceutical forms
- describe suspensions in oil
- describe preparation of injection compositions
- describe preparation of oral compositions
- define rate controlling polymer
- list examples of controlled release polymers
- describe composition of controlled release preparation
- list auxiliary agents
- describe manufacturing methods
- describe oral dosage forms
- describe pharmaceutical compositions for rectal administration
- describe pharmaceutical compositions for parenteral administration
- describe ointments
- describe fatty ointments
- describe creams
- describe pastes
- describe foams
- describe tinctures and solutions
- describe co-administered formulations
- list anti-cancer agents
- list antiviral agents
- list antimicrobial agents
- list antifungal agents
- define disease state or condition
- describe method of treatment
- define treatment and effective amount
- describe process for treatment of disease states
- list disease states or conditions that can be treated
- list diseases
- list additional diseases
- define cancer
- list exemplary cancers
- describe therapeutic methods
- identify subjects in need of treatment
- describe administration of compounds
- provide methods of making and using compounds
- describe diagnostic agent use
- describe method of monitoring treatment progress
- determine level of diagnostic marker
- compare levels of marker
- describe dosage of active compound
- describe unit dosage form
- describe oral dosage
- describe achieving peak plasma concentrations
- describe intravenous injection
- describe oral administration
- describe methods of preparation
- provide additional methods for synthesis

### Examples

- introduce peptide-oligourea hybrid design
- motivate GLP-1-NH2 modification
- describe consecutive amino acid residues replacement
- discuss side chain projection of Xu residues
- introduce Alau triad scan
- describe functional assay for agonistic activity
- summarize results of Alau triad scan
- reintroduce native side chains in oligourea triads
- discuss results of reintroducing native side chains
- introduce enzymatic and mouse plasma degradation studies
- describe NEP 24.11 degradation assay
- discuss results of NEP 24.11 degradation assay
- describe mouse plasma degradation assay
- discuss results of mouse plasma degradation assay
- introduce in vivo studies
- describe effect of analogues on blood glucose concentration
- discuss results of in vivo studies
- summarize conclusions and future directions
- describe in vitro pharmacology
- describe enzymatic degradation
- describe mouse plasma stability
- describe in vivo studies in mice
- describe blood glucose experiment in healthy mice
- describe ipgtt experiments in mice
- describe pharmacokinetics
- perform statistical analysis
- synthesize azido building block
- synthesize monomer M1
- synthesize monomer M2
- describe general procedure for synthesizing oligomers
- detail steps for synthesizing oligomers
- describe procedure for reducing azide group
- describe procedure for cleaving from resin
- describe purification and characterization methods
- describe alternative procedure for synthesizing oligomer 25
- describe synthesis procedure C
- detail synthesis of peptide 1
- detail synthesis of peptide-oligourea hybrids 2-14
- describe characterization of oligomers 1-25
- present EC50 determination results for peptide-oligourea hybrids 1-14
- present enzymatic degradation results for peptide-oligourea hybrids 2, 5, 9, 11
- present mouse plasma degradation results for peptide-oligourea hybrids 2, 5, 9, 11
- provide HPLC and LC-MS data for peptide-oligourea hybrids 1-14
- illustrate concentration-response curves for peptide-oligourea hybrids 1-14
- describe peptide-oligourea hybrids
- synthesize and characterize peptide-oligourea hybrids
- demonstrate concentration-response curves
- demonstrate enzymatic degradation
- demonstrate mouse plasma degradation
- demonstrate NEP 24.11 degradation assay
- demonstrate mouse plasma degradation assay
- demonstrate pancreatin degradation assay
- demonstrate IPGTT 2 h after dosing
- evaluate agonist activity
- demonstrate concentration-response curves (second method)
- discuss experimental results
- provide concluding remarks

